Abstracts Archive - Page 112 of 2607 - ACR Meeting Abstracts

Abstract Number: 1334 • ACR Convergence 2025
Cardiac Biomarkers and Prediction of Major Cardiovascular Events in Rheumatoid Arthritis: Results from the ESPOIR Cohort
manon lesturgie¹, Fiona Oudart¹, Anne Cauvet², Virginie Gonzalez², Bruno Fautrel³, Arnaud Constantin⁴, Nathalie Rincheval⁵, Yannick Allanore⁶ and Jérôme Avouac⁷, ¹INSERM U¹⁰¹⁶, Paris, France, ²INSERMU¹⁰¹⁶, Paris, France, ³Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ⁴Hôpital Pierre-Paul Riquet, CHU Purpan, Toulouse, France, ⁵Institut de Recherche Clinique EA²⁴¹⁵, Université de Montpellier, Département de Statistiques, Montpellier, France, ⁶Université Paris Cité, Paris, France, ⁷Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Patients with rheumatoid arthritis (RA) experience premature mortality, largely due to cardiovascular (CV) disease. The increased CV risk is due to both the underlying…
Abstract Number: 1340 • ACR Convergence 2025
Does Moderate Alcohol Use Lower Disease Activity Among Patients with Rheumatoid Arthritis?
Sarah Crisci¹, Joshua Baker², Kevin Kane³, George Reed⁴, Dimitrios Pappas⁵ and Joel Kremer⁶, ¹New York University, New York, NY, ²University of Pennsylvania, Philadelphia, PA, ³University of Massachusetts Lowell, Lowell, MA, ⁴University of Massachusetts Chan Medical School, Worcester, MA, ⁵CorEvitas, New York, NY, ⁶The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: The relationship between alcohol use and disease activity among patients with rheumatoid arthritis (RA) remains controversial. Several studies have concluded that moderate drinking may…
Abstract Number: 1273 • ACR Convergence 2025
Effectiveness of IV Cyclophosphamide and Mycophenolate Mofetil in the Treatment of Pediatric Systemic Lupus Erythematosus with Lupus Nephritis
adrienne katrin guiang-valerio, University of Santo Tomas Hospital, Mandaluyong, National Capital Region, Philippines
Background/Purpose: Lupus nephritis (LN) is more common in children (occurs in 50-82%) compared to adults. Cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are both treatment options…
Abstract Number: 1299 • ACR Convergence 2025
Pediatric Antiphospholipid Syndrome in a Large Tertiary Center
Rasha Elrefai, Marietta De Guzman, Jun Teruya, Vadim Kostousov, Amir Navaei and Olivia Kwan, Baylor College of Medicine, Houston, TX
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune condition defined as the presence of thrombotic events and/or pregnancy morbidity, accompanied by persistent antiphospholipid antibodies (aPLs). Pediatric…
Abstract Number: 1379 • ACR Convergence 2025
Renal tubular acidosis in Sjögren’s disease and non-Sjögren’s sicca in an Oklahoma cohort
Biji T Kurien¹, Martha Tsaliki² and R Hal Scofield¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²OMRF, Oklahoma City, OK
Background/Purpose: Renal involvement in primary Sjögren’s disease (pSjD) is a well-known extraglandular manifestation with a prevalence of 5-14% in several studies. Mostly, it affects the…
Abstract Number: 1344 • ACR Convergence 2025
Exploring the Factors Associated with the Discontinuation of Tofacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
yao fan fang¹, Ping-Han Tsai² and yen Fu CHEN³, ¹Chang Gung memorial hopspital, Linkou, Taipei, New Taipei, Taiwan (Republic of China), ²Chang Gung memorial hospital, linkou, Taipei, Taiwan (Republic of China), ³Chang Gung memoriial hospital linkou, taipei, Taiwan (Republic of China)
Background/Purpose: Tofacitinib is the first oral targeted synthetic disease-modify anti-rheumatic drug for patients with moderate to severe rheumatoid arthritis 1. This study aimed to identify…
Abstract Number: 1352 • ACR Convergence 2025
Prediction of 5-Year Fracture Risk in Rheumatoid and Psoriatic Arthritis Using REMS Technology
Marco Di Paola¹, Edmund J MacLaughlin², Kathleen Methric³, Maurizio Muratore⁴, Gianmarco Del Vecchio⁵, Giusy Peluso⁶, Ernesto Casciaro¹, Fabiola Rosa Contaldo⁷, Fiorella Anna Lombardi¹, Paola Pisani¹, Francesco Conversano¹ and Sergio Casciaro¹, ¹Institute of Clinical Physiology, National Research Council, Lecce, Puglia, Italy, ²Rheumatology Associates of Delmarva and BoneVue Diagnostics, Easton, MD, ³BoneVue Diagnostics, Catonsville, MD, ⁴ASL- LE, "Vito Fazzi" Hospital, Lecce, Puglia, Italy, ⁵Department of Research and Development, Echolight S.p.a., Lecce, Puglia, Italy, ⁶Department of Innovative Engineering, University of Salento, Lecce, Puglia, Italy, ⁷Department of Biological and Environmental Sciences and Technologies, University of Salento, University of Salento, Lecce, Puglia, Italy
Background/Purpose: Autoimmune arthritis, including Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PA), are among the most common forms of inflammatory joint diseases. These conditions affect joints…
Abstract Number: 1355 • ACR Convergence 2025
Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance ofbeing off steroids and escalation of therapy at 1 year
Andreu Fernandez Codina¹, Marie-France Valois², Susan J. Bartlett³, Mishquatul Wahed⁴, Hugues Allard-Chamard⁵, Louis Bessette⁶, Glen Hazlewood⁷, Carol Hitchon⁸, Bindee Kuriya⁹, Vivian Bykerk¹⁰ and Janet Pope¹¹, ¹Western University, London, ON, Canada, ²McGill University, Pointe-Claire, QC, Canada, ³McGill University, Beaconsfield, QC, Canada, ⁴Western University, Windsor, ON, Canada, ⁵Université de Sherbrooke, Sherbrooke, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University of Toronto - Toronto, Toronto, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹University of Western Ontario, London, ON, Canada
Background/Purpose: The 2023 EULAR recommendations for the management of Rheumatoid Arthritis (RA) emphasizes theimportance of limiting the dose and duration of glucocorticoids (GC) used in…
Abstract Number: 1275 • ACR Convergence 2025
Fostering connections in Pediatric Rheumatology: A Narrative medicine intervention
Anita Dhanrajani¹, Joanne Drew², Suzanne Edison³, Lakshmi Moorthy⁴, Ingrid Goh⁵, Alicia Garceau⁶, Hanna Saltzman⁷, Courtney Wells⁸ and Aviya Levy⁹, ¹Manning Family Children's Hospital, Tulane University Medicine, New Orleans, LA, ²Nationwide Children's Hospital, Columbus, OH, ³Cure JM foundation, Seattle, WA, ⁴Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁵University of Toronto The Hospital for Sick Children, Toronto, ON, Canada, ⁶Self Employed, Indianapolis, ⁷University of Utah, Salt Lake City, UT, ⁸University of Wisconsin River falls, River Falls, WI, ⁹Rady Children's Hospital, San Diego, CA
Background/Purpose: Patients with chronic diseases often report poor health-related quality of life (QOL) and impaired psychosocial functioning. The current model of healthcare in rheumatology emphasizes…
Abstract Number: 1317 • ACR Convergence 2025
The Association Between Insomnia and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 546,822 Patients
Mohamed Abdelsalam¹, Maryam Lasheen², Menat Alla Ayman Ali Mahdy³, Hadeer Hafez⁴, Nourhan Abouelella⁵, Mohamed Al-Adl⁶ and Mohamed Reda Awad⁷, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ³Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Faculty of Medicine, Misr University for Science and Technology, ⁶ october, Al Jizah, Egypt, ⁶Faculty of medicine Al-Azhar University Cairo, Nasr City, Egypt, ⁷Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Insomnia and rheumatoid arthritis (RA) are caught in a snowball effect, where chronic pain disrupts sleep and causes poor sleep quality, which in turn…
Abstract Number: 1281 • ACR Convergence 2025
Ethnic Disparities in Mental Health Screening, Diagnoses, and Outcomes in Patients with Childhood-Onset Systemic Lupus Erythematosus
Alicia Tran¹, Indrani Das², Zhaoyu Ding³, Daniela Dominguez⁴, Sefi Kronenberg⁵, Lawrence Ng⁶, Alene Toulany¹, Gwyneth Zai⁷, Deborah Levy¹, Andrea Knight⁸ and Linda Hiraki¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³SickKids Research Institute, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, Canada, ⁵Holland Bloorview Kids Rehabilitation Hospital, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁷Centre for Addiction & Mental Health, Toronto, ON, Canada, ⁸Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) face higher risks of depression and anxiety compared to healthy peers. In 2022, standardized mental health (MH)…
Abstract Number: 1362 • ACR Convergence 2025
Multimodal Spatial and Single-Cell Profiling of Synovial Tissue Reveals Macrophage Programs Associated with Biologic TherapyTreatment Response in Rheumatoid Arthritis
Mohammad Daud Khan¹, Matthew Dapas², Salina T Dominguez¹, Tyler Therron³, Kathleen Aren⁴, Mary Carns⁵, Hadijat Makinde⁵, Arthur M Mandelin¹, Eric M Ruderman¹, John F Seagrist⁵, Ruth Misha¹, Carla Marie Cuda⁵, Harris R Perlman⁵ and Deborah Rachelle Winter⁶, ¹Northwestern University, Chicago, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Northwestern Feinberg School of Medicine, Chicago, IL, ⁴Northwestern University Division of Rheumatology, Chicago, IL, ⁵Northwestern University, Chicago, IL, ⁶Northwestern University, Skokie, IL
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease driven by persistent synovial inflammation and progressive joint damage. Selecting an effective biologic therapy remains a…
Abstract Number: 1358 • ACR Convergence 2025
Real-World Evidence for the Superiority of Subcutaneous Methotrexate in RA: A Comparative Observational Study with Ultrasonographic Assessment
Masatsugu Komagamine¹, Sari Taguchi², Masataka Komagamine², Tetsuji Naka¹ and Minoru Fujimoto¹, ¹Division of Allergy and Rheumatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan, ²Komagamine Rheumatology and Orthopedic Clinic, Morioka, Japan
Background/Purpose: Methotrexate (MTX) is a foundational agent in the management of rheumatoid arthritis (RA). While oral MTX is widely prescribed, its subcutaneous (SC) formulation may…
Abstract Number: 1361 • ACR Convergence 2025
Efficacy of Telitacicept in the treatment of Connective tissue disease-associated interstitial lung disease: A Potential therapeutic option
Mingfang Sun¹, Xue Chen², Ying Zhou², Yanlong Yang², Fei Xiao² and huanzi dai², ¹Daping Hospital, chongqing, China (People's Republic), ²Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing, PR China., Chongqing, China (People's Republic)
Background/Purpose: Connective tissue disease-associated interstitial lung disease(CTD-ILD) represents a significant cause of mortality among patients. Presently, research on treatment options for CTD-ILD is limited, with…
Abstract Number: 1286 • ACR Convergence 2025
Response to Hydroxychloroquine in Immune Thrombocytopenia in Childhood-Onset Systemic Lupus Erythematosus
Hamada Natour¹, Y. Ingrid Goh¹, Daniela Dominguez², Nicholas Gold¹, Lawrence Ng³, Andrea Knight⁴, Earl Silverman¹, Brian Feldman¹, Linda Hiraki¹ and Deborah Levy¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, Canada, ³The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: The management of immune thrombocytopenia in childhood-onset systemic lupus erythematosus (cSLE) is not standardized. We examined the efficacy and safety of hydroxychloroquine (HCQ) as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].